Cytokinetics Inc (CYTK)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$69.21

Buy

$69.55

arrow-down$-0.05 (-0.07%)

Prices updated at 12 Jun 2026, 14:38 EDT

Prices minimum 15 mins delay

Prices in USD

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle p ...

NASDAQ

-0.18%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Dr. John T. Henderson, M.B.

CEO

Mr. Robert I. Blum

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

673

Head office

350 Oyster Point Boulevard

South San Francisco

United States

94080

+1 650 624-3000

investor@cytokinetics.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Ms. B. Lynne Parshall, Esq.,J.D. Independent Director	0.10m
Dr. John T. Henderson, M.B. Chairman of the Board	0.04m
Ms. Nancy J. Wysenski Independent Director	0.06m
Mr. Robert I. Blum Director, President and Chief Executive Officer	0.85m
Dr. Wendell D. Wierenga,PhD Independent Director	0.06m
Dr. Edward M. Kaye, M.D. Independent Director	0.04m
Dr. Fady Ibraham Malik, M.D.,PhD Executive Vice President, Research and Development	0.63m
Mr. James M. Daly Independent Director	0.02m
Mr. Robert E. Landry Independent Director	0.05m
Mr. Jeffrey J. Hessekiel Executive Vice President, Chief Legal and Administrative Officer	0.09m
Mr. Sung H. Lee Executive Vice President, Chief Financial Officer and Principal Accounting Officer	0.57m
Ms. Muna Bhanji, Ph. Independent Director	0.08m
Mr. Andrew M. Callos Executive Vice President and Chief Commercial Officer	0.58m
Dr. Robert A. Harrington, M.D. Independent Director	0.01m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
T. Rowe Price Investment Management,Inc.	17,523,840
BlackRock Inc	16,548,011
Vanguard Group Inc	12,048,131
BlackRock Fund Advisors	10,853,959
FMR Inc	10,723,140

Director dealings

Date chevron-l-regular chevron-r-regular	Action
29 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-
22 Dec 2025	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.